EHA 2016 | EURO-SKI trial: stopping tyrosine kinase inhibitors in a very large cohort of European CML patients
Press brief by Johan Richter, MD, PhD of the Skåne University Hospital Lund, Lund, Sweden, at the 2016 Annual Meeting of the European Association of Hematology (EHA), held in Copenhagen, Denmark.
Get great new content delivered to your inboxSign up
CML-IT-MOS: clinical characteristics of CML patients not included in clinical trials
Generic vs. branded imatinib for CP-CML: a multicenter, observational study
Asciminib: overcoming TKI resistance and reducing toxicity in CML
Predictors for TFR in CML: response duration, secondary treatment & frontline TKI choice
Update on ENESTop: TFR in CML after discontinuing nilotinib